Venous Thromboembolism Treatment in Cancer Patients

New Orleans, LA US
October 1, 2020

Patients with cancer are 4 to 6.5 times more likely to develop venous thromboembolisms (VTE) than the general population. Additionally, VTE in cancer patients is the 2nd most common cause of cancer related death. Different types of cancers, having a central venous catheter for chemotherapy, and the chemotherapy agents are risk factors for thrombosis in cancer patients. There are two major guidelines that address the use of anticoagulation for cancer related VTE: American Society of Clinical Oncology Journal (ASCO) and National Comprehensive Cancer Network (NCCN). Traditionally, enoxaparin had been the gold standard treatment option for anticoagulation in cancer related VTE. However, this is an injection that patients would have to give to themselves, requiring education on proper technique and handling. Direct oral anticoagulants (DOACs) are commonly used for non-cancer related VTE, however, their use for VTE in cancer patients is an important clinical question There have been newer studies to show that DOACs including edoxaban, apixaban, and rivaroxaban, may be safe and effective to be used in cancer related VTE. This presentation will review the primary literature behind the use of the DOACs in cancer patients and identify its place in practice.

Target Audience

  • Pharmacists
  • Pharmacy technicians

Learning Objectives

Pharmacist learning objectives
  1. Describe the epidemiology and pathophysiology of venous thromboembolisms in cancer patients
  2. Discuss risk factors for thrombosis in cancer patients
  3. Compare the anticoagulation recommendations put forth by the American Society of Clinical Oncology Journal (ASCO) and National Comprehensive Cancer Network (NCCN)
  4. Evaluate the literature on the use of direct acting anticoagulants in cancer patients and recognize their place in practice
Pharmacy technician learning objectives
  1. Recognize brand/generic names of the anticoagulation agents used in the treatment of VTE
  2. Identify the different dosage forms of the anticoagulation agents

Additional Information

Course summary
Available credit: 
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
  • 1.00 General CEU – Attendance
Course opens: 
10/01/2020
Course expires: 
11/15/2020
Event starts: 
10/01/2020 - 12:00pm
Event ends: 
10/01/2020 - 1:00pm
Cost:
$0.00
Ochsner Medical Center
1514 Jefferson Hwy.
New Orleans, LA 70121
United States
Relevant financial relationships: Planning committee members and presenters have nothing to disclose
 
Planning committee members
 
Kyle Barron, PharmD, BCPS
Clinical Pharmacist
Ochsner Medical Center
 
Bailey Wise, PharmD
Clinical Pharmacist
Ochsner Medical Center
 
Julia Roh, PharmD
PGY-2 Pharmacy Resident
Ochsner Medical Center
 
Presenter
 
Julia Roh, PharmD
PGY-2 Pharmacy Resident
Ochsner Medical Center
Joint Accreditation Statement:
 
In support of improving patient care, this activity has been planned and implemented by Vizient, Inc. and Ochsner Medical Center.  Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
____________________________________________
 
Designation Statements:
 
PHARMACY
Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.
Universal Activity Number: JA0006103-9999-20-178-L01-P
Universal Activity Number: JA0006103-9999-20-178-L01-T
CEU
Vizient, Inc. will award CEUs to each participant who successfully completes this program. The CEU is a nationally recognized unit of measure for continuing education and training programs that meet certain criteria (1 contact hour = 0.1 CEU).

Available Credit

  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
  • 1.00 General CEU – Attendance

Price

Cost:
$0.00
Please login or register to take this course.